High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer

被引：10

作者：

Fujita, Ken-ichi ^{[1
,2
]}

Hirose, Takashi ^{[3
,4
]}

Kusumoto, Sojiro ^{[3
]}

Sugiyama, Tomohide ^{[3
]}

Shirai, Takao ^{[3
]}

Nakashima, Masanao ^{[3
]}

Akiyama, Yuko ^{[1
]}

Sasaki, Yasutsuna ^{[1
,2
,5
]}

机构：

[1] Saitama Med Univ, Comprehens Canc Ctr, Int Med Ctr, Dept Med Oncol, Hidaka, Saitama 3501298, Japan

[2] Showa Univ, Inst Mol Oncol, Tokyo 1428555, Japan

[3] Showa Univ, Dept Internal Med, Div Resp Med & Allergol, Tokyo 1428666, Japan

[4] Tokyo Natl Hosp, Natl Hosp Org, Dept Respirol, Kiyose, Tokyo 2048585, Japan

[5] Showa Univ, Sch Med, Dept Med Oncol, Tokyo 1428666, Japan

来源：

LUNG CANCER | 2014年 / 86卷 / 01期

关键词：

Erlotinib; Interstitial lung disease; Pharmacokinetics; High exposure; ABCG2; Polymorphism; JAPANESE PATIENTS; PHARMACOKINETICS/PHARMACODYNAMICS; PLASMA;

D O I：

10.1016/j.lungcan.2014.07.021

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：113 / 114

页数：2

共 5 条

[1] A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma [J].

Faivre, Lionel ;

Gomo, Charline ;

Mir, Olivier ;

Taieb, Fabrice ;

Schoemann-Thomas, Audrey ;

Ropert, Stanislas ;

Vidal, Michel ;

Dusser, Daniel ;

Dauphin, Alain ;

Goldwasser, Francois ;

Blanchet, Benoit .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2011, 879 (23) :2345-2350

[2] Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer [J].

Fukudo, Masahide ;

Ikemi, Yasuaki ;

Togashi, Yosuke ;

Masago, Katsuhiro ;

Kim, Young Hak ;

Mio, Tadashi ;

Terada, Tomohiro ;

Teramukai, Satoshi ;

Mishima, Michiaki ;

Inui, Ken-ichi ;

Katsura, Toshiya .

CLINICAL PHARMACOKINETICS, 2013, 52 (07) :593-609

[3] Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer A Phase II Study [J].

Kubota, Kaoru ;

Nishiwaki, Yutaka ;

Tamura, Tomohide ;

Nakagawa, Kazuhiko ;

Matsui, Kaoru ;

Watanabe, Koshiro ;

Hida, Toyoaki ;

Kawahara, Masaaki ;

Katakami, Nobuyuki ;

Takeda, Kohi ;

Yokoyama, Akira ;

Noda, Kazumasa ;

Fukuoka, Masahiro ;

Saijo, Nagahiro .

JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (12) :1439-1445

[4] Population Differences in Major Functional Polymorphisms of Pharmacokinetics/pharmacodynamics-related Genes in Eastern Asians and Europeans: Implications in the Clinical Trials for Novel Drug Development [J].

Kurose, Kouichi ;

Sugiyama, Emiko ;

Saito, Yoshiro .

DRUG METABOLISM AND PHARMACOKINETICS, 2012, 27 (01) :9-54

[5] Erlotinib in previously treated non-small-cell lung cancer [J].

Shepherd, FA ;

Pereira, JR ;

Ciuleanu, T ;

Tan, EH ;

Hirsh, V ;

Thongprasert, S ;

Campos, D ;

Maoleekoonpiroj, S ;

Smylie, M ;

Martins, R ;

van Kooten, M ;

Dediu, M ;

Findlay, B ;

Tu, DS ;

Johnston, D ;

Bezjak, A ;

Clark, G ;

Santabárbara, P ;

Seymour, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :123-132

← 1 →